Dingxian He
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Dingxian He has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Sushan Luo
Huashan Rare Disease Center and Department of Neurology, Huashan Hospital, Shanghai Medical College, National Center for Neurological Disorders, Fudan University
4 shared publications Chong Yan
Fudan University
3 shared publications- Chongbo Zhao
Huashan Rare Disease Center, Department of Neurology, Huashan Hospital, Fudan University, Shanghai, China
3 shared publications Jianying Xi
Fudan University
2 shared publicationsHong Jin
The Second Affiliated Hospital of Soochow University
1 shared publicationHuahua Zhong
Fudan University
1 shared publication
Latest Publications
- Open Access
- 1 October 2026
- Published by SAGE Publications in Therapeutic Advances in Neurological Disorders
- Vol. 19
Dual targeting complement C5 and BAFF/APRIL in highly active myasthenia gravis: A prospective case series
Background: Highly active Generalised myasthenia gravis (gMG) represents a group of patients with substantial disability and recurrent, life-threatening exacerbations. The recent emergence of targeted biologics has created new therapeutic opportunities, yet the potential of dual targeting complement C5 and B-cell signaling, such as B cell activating factor (BAFF)/proliferation-inducing ligand (APRIL), has not been thoroughly explored in these patients. Objectives: To explore the efficacy and safety of combined therapies with eculizumab (C5 complement inhibitor) and telitacicept (BAFF/APRIL inhibitor) in acetylcholine receptor antibody (AChR-ab)+ gMG patients who had high disease activity. Design: Single-centre, prospective, observational case series. Methods: Patients with highly active gMG despite advanced immunotherapies were enrolled in a neuromuscular reference centre for treatment with eculizumab and telitacicept. The primary endpoint was the change in Myasthenia Gravis Activities of Daily Living (MG-ADL) score. Minimal Symptom Expression (MSE), Clinically Meaningful Improvement (CMI), oral corticosteroid dose, serum IgG, and the incidence of treatment-emergent adverse events (TEAEs) were assessed. Results: Among the 22 patients ultimately enrolled, 16 (72.7%) had a history of myasthenic crisis (MC). Previously administered immunomodulatory therapies included intravenous immunoglobulin (IVIG) (16/22, 72.7%), efgartigimod (14/22, 63.6%), and plasma exchange (PE) (13/22, 59.1%). At Week 12 after initiation of eculizumab and telitacicept, significant improvements were observed: the MG-ADL score decreased substantially from a baseline value of 8.0 (IQR 5.0–10.0) to 1.0 (IQR 0.0–2.8) (p < 0.001), with all participants achieving CMI and 54.5% (12/22, 95% CI 32.2–75.6) achieving MSE. Concurrently, the daily oral prednisone dose was significantly reduced by 33% (from 22.5 mg to 15.0 mg; p < 0.001), and serum IgG levels declined markedly from 11.86 g/L to 7.14 g/L (p < 0.001). Notably, no meningococcal infections or other serious adverse events were reported. Conclusion: In highly active AChR-ab+ gMG requiring rapid disease control, simultaneous targeting of complement C5 and B cell activating pathway achieved clinical improvement, corticosteroid sparing, and reduced serum IgG, with an acceptable short-term safety profile. These proof-of-concept findings require confirmation in controlled trials with a mono-targeting therapy regimen and longer follow-up.
- 1 October 2026
- Published by SAGE Publications in Therapeutic Advances in Neurological Disorders
- Vol. 19
Open AccessDual targeting complement C5 and BAFF/APRIL in highly active myasthenia gravis: A prospective case series
Background: Highly active Generalised myasthenia gravis (gMG) represents a group of patients with substantial disability and recurrent, life-threatening exacerbations. The recent emergence of targeted biologics has created new therapeutic opportunities, yet the potential of dual targeting complement C5 and B-cell signaling, such as B cell activating factor (BAFF)/proliferation-inducing ligand (APRIL), has not been thoroughly explored in these patients. Objectives: To explore the efficacy and safety of combined therapies with eculizumab (C5 complement inhibitor) and telitacicept (BAFF/APRIL inhibitor) in acetylcholine receptor antibody (AChR-ab)+ gMG patients who had high disease activity. Design: Single-centre, prospective, observational case series. Methods: Patients with highly active gMG despite advanced immunotherapies were enrolled in a neuromuscular reference centre for treatment with eculizumab and telitacicept. The primary endpoint was the change in Myasthenia Gravis Activities of Daily Living (MG-ADL) score. Minimal Symptom Expression (MSE), Clinically Meaningful Improvement (CMI), oral corticosteroid dose, serum IgG, and the incidence of treatment-emergent adverse events (TEAEs) were assessed. Results: Among the 22 patients ultimately enrolled, 16 (72.7%) had a history of myasthenic crisis (MC). Previously administered immunomodulatory therapies included intravenous immunoglobulin (IVIG) (16/22, 72.7%), efgartigimod (14/22, 63.6%), and plasma exchange (PE) (13/22, 59.1%). At Week 12 after initiation of eculizumab and telitacicept, significant improvements were observed: the MG-ADL score decreased substantially from a baseline value of 8.0 (IQR 5.0–10.0) to 1.0 (IQR 0.0–2.8) (p < 0.001), with all participants achieving CMI and 54.5% (12/22, 95% CI 32.2–75.6) achieving MSE. Concurrently, the daily oral prednisone dose was significantly reduced by 33% (from 22.5 mg to 15.0 mg; p < 0.001), and serum IgG levels declined markedly from 11.86 g/L to 7.14 g/L (p < 0.001). Notably, no meningococcal infections or other serious adverse events were reported. Conclusion: In highly active AChR-ab+ gMG requiring rapid disease control, simultaneous targeting of complement C5 and B cell activating pathway achieved clinical improvement, corticosteroid sparing, and reduced serum IgG, with an acceptable short-term safety profile. These proof-of-concept findings require confirmation in controlled trials with a mono-targeting therapy regimen and longer follow-up.
- Open Access
- 26 July 2026
- Published by Taylor & Francis in Expert Review of Vaccines
- Vol. 25 (1)
When precision medicine meets rigid vaccination: bridging the policy gap for patients on biologics
1. Precision medicine therapies such as complement inhibitors have transformed outcomes for paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome (aHUS), IgA nephropathy, myasthen...
- 26 July 2026
- Published by Taylor & Francis in Expert Review of Vaccines
- Vol. 25 (1)
Open AccessWhen precision medicine meets rigid vaccination: bridging the policy gap for patients on biologics
1. Precision medicine therapies such as complement inhibitors have transformed outcomes for paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome (aHUS), IgA nephropathy, myasthen...
- Open Access
- 21 March 2025
- Published by SAGE Publications in Therapeutic Advances in Neurological Disorders
- Vol. 18
Efgartigimod for induction and maintenance therapy in muscle-specific kinase myasthenia gravis
Background: The efficacy of efgartigimod in treating myasthenia gravis (MG) patients with muscle-specific kinase (MuSK) antibodies has not been demonstrated in the clinical trial, existing case reports, or observational studies. Objectives: To evaluate the efficacy and safety of efgartigimod combined with immunotherapies such as tacrolimus or B-cell depleting agents, as maintenance treatment for MuSK-MG patients. Design: This retrospective study included 14 MuSK-MG patients treated with efgartigimod at three tertiary hospitals from 2023 to 2024. Methods: Data on the activities of daily living (ADL) scores, Quantitative Myasthenia Gravis scores, and the time reaching minimal symptom expression (MSE) were collected. The combined use of steroids, immunosuppressants, and rescue therapies, as well as the adverse event incidence, were also recorded. Results: The mean age at first efgartigimod treatment was 55 ± 18 years old with a median follow-up time of 28 weeks. From baseline to week 4, MG-ADL scores decreased significantly from 10.1 ± 4.0 to 2.2 ± 3.1 ( n = 14, p = 0.001). The majority of patients (92.9%) maintains a reduction of at least 2 points for more than 8 weeks. The median time to achieve MSE was 4 weeks, with 71.4% (10/14) of patients reaching MSE by week 12. In patients receiving CD20 B cell depleting therapy or tacrolimus as maintenance, the time-weighted average dosage of prednisone was 16 mg while that in those with prednisone alone was 37 mg. Of all the 14 patients, one developed an upper respiratory tract infection 4 weeks after rituximab (RTX), and one was infected with herpes zoster virus 13 weeks after RTX. Conclusion: A single-cycle efgartigimod as an induction therapy, combined with immunotherapies such as tacrolimus or B cell depleting agents, as maintenance treatment, could benefit MuSK-MG patients.
- 21 March 2025
- Published by SAGE Publications in Therapeutic Advances in Neurological Disorders
- Vol. 18
Open AccessEfgartigimod for induction and maintenance therapy in muscle-specific kinase myasthenia gravis
Background: The efficacy of efgartigimod in treating myasthenia gravis (MG) patients with muscle-specific kinase (MuSK) antibodies has not been demonstrated in the clinical trial, existing case reports, or observational studies. Objectives: To evaluate the efficacy and safety of efgartigimod combined with immunotherapies such as tacrolimus or B-cell depleting agents, as maintenance treatment for MuSK-MG patients. Design: This retrospective study included 14 MuSK-MG patients treated with efgartigimod at three tertiary hospitals from 2023 to 2024. Methods: Data on the activities of daily living (ADL) scores, Quantitative Myasthenia Gravis scores, and the time reaching minimal symptom expression (MSE) were collected. The combined use of steroids, immunosuppressants, and rescue therapies, as well as the adverse event incidence, were also recorded. Results: The mean age at first efgartigimod treatment was 55 ± 18 years old with a median follow-up time of 28 weeks. From baseline to week 4, MG-ADL scores decreased significantly from 10.1 ± 4.0 to 2.2 ± 3.1 ( n = 14, p = 0.001). The majority of patients (92.9%) maintains a reduction of at least 2 points for more than 8 weeks. The median time to achieve MSE was 4 weeks, with 71.4% (10/14) of patients reaching MSE by week 12. In patients receiving CD20 B cell depleting therapy or tacrolimus as maintenance, the time-weighted average dosage of prednisone was 16 mg while that in those with prednisone alone was 37 mg. Of all the 14 patients, one developed an upper respiratory tract infection 4 weeks after rituximab (RTX), and one was infected with herpes zoster virus 13 weeks after RTX. Conclusion: A single-cycle efgartigimod as an induction therapy, combined with immunotherapies such as tacrolimus or B cell depleting agents, as maintenance treatment, could benefit MuSK-MG patients.
- Open Access
- 1 January 2024
- Published by SAGE Publications in Therapeutic Advances in Neurological Disorders
- Vol. 17
Eculizumab in thymoma-associated myasthenia gravis: a real-world cohort study
Background: Thymoma-associated myasthenia gravis (TAMG) is a subtype of myasthenia gravis (MG) that is associated with more severe symptoms and a relatively poor prognosis. Eculizumab, an inhibitor to target human C5 component of the complement cascade, is considered a treatment option for refractory generalized MG (gMG). Objectives: To explore the safety and efficacy of eculizumab in patients with TAMG. Design: This is an observational multicenter real-world cohort study to assess TAMG who were treated with eculizumab from June 2023 to June 2024. Data sources and methods: Clinical features associated with thymoma-associated multi-organ autoimmunity (TAMA), Myasthenia Gravis Activities of Daily Living (MG-ADL) score, and the incidence of treatment-emergent adverse events (TEAEs) were prospectively collected. Results: Overall, 42 patients with gMG were treated with eculizumab at 5 research centers, of whom 22 patients with TAMG were finally included. This cohort had a mean age of 51.5 ± 12.1 years and an average disease duration of 4.0 ± 4.3 years. Regarding thymomas, the World Health Organization (WHO) histological classification was primarily B2 and B3 (63.7%), and Masaoka staging was predominantly IV (45.5%). Nine participants (40.9%) switched from efgartigimod to eculizumab aiming at a better clinical improvement and reducing steroid use. By week 12, the MG-ADL score decreased to 4.8 ± 4.7 (baseline: 11.7 ± 6.0), and the corticosteroid dose reduced to 23.2 ± 26.5 mg (baseline: 41.8 ± 63.9 mg). Two patients with TAMA showed significant improvement in skin lesions and thrombocytopenia. Two TEAEs were recorded including COVID-19 and herpes labialis infection. Four patients (18.2%) died of respiratory or circulatory failure owing to thymoma metastasis. Conclusion: This real-world study demonstrates the efficacy of eculizumab in achieving symptom control and corticosteroid reduction for TAMG. It may also be a therapeutic option for refractory TAMG and TAMA. Trial registration: NCT04535843.
- 1 January 2024
- Published by SAGE Publications in Therapeutic Advances in Neurological Disorders
- Vol. 17
Open AccessEculizumab in thymoma-associated myasthenia gravis: a real-world cohort study
Background: Thymoma-associated myasthenia gravis (TAMG) is a subtype of myasthenia gravis (MG) that is associated with more severe symptoms and a relatively poor prognosis. Eculizumab, an inhibitor to target human C5 component of the complement cascade, is considered a treatment option for refractory generalized MG (gMG). Objectives: To explore the safety and efficacy of eculizumab in patients with TAMG. Design: This is an observational multicenter real-world cohort study to assess TAMG who were treated with eculizumab from June 2023 to June 2024. Data sources and methods: Clinical features associated with thymoma-associated multi-organ autoimmunity (TAMA), Myasthenia Gravis Activities of Daily Living (MG-ADL) score, and the incidence of treatment-emergent adverse events (TEAEs) were prospectively collected. Results: Overall, 42 patients with gMG were treated with eculizumab at 5 research centers, of whom 22 patients with TAMG were finally included. This cohort had a mean age of 51.5 ± 12.1 years and an average disease duration of 4.0 ± 4.3 years. Regarding thymomas, the World Health Organization (WHO) histological classification was primarily B2 and B3 (63.7%), and Masaoka staging was predominantly IV (45.5%). Nine participants (40.9%) switched from efgartigimod to eculizumab aiming at a better clinical improvement and reducing steroid use. By week 12, the MG-ADL score decreased to 4.8 ± 4.7 (baseline: 11.7 ± 6.0), and the corticosteroid dose reduced to 23.2 ± 26.5 mg (baseline: 41.8 ± 63.9 mg). Two patients with TAMA showed significant improvement in skin lesions and thrombocytopenia. Two TEAEs were recorded including COVID-19 and herpes labialis infection. Four patients (18.2%) died of respiratory or circulatory failure owing to thymoma metastasis. Conclusion: This real-world study demonstrates the efficacy of eculizumab in achieving symptom control and corticosteroid reduction for TAMG. It may also be a therapeutic option for refractory TAMG and TAMA. Trial registration: NCT04535843.